Medicine and Dentistry
Sorafenib
100%
Combination Therapy
75%
Hepatocellular Carcinoma
50%
Upregulation
50%
Transcatheter Arterial Chemoembolization
50%
Ischemia
25%
Tumor Angiogenesis
25%
Vasculotropin
25%
Vasculotropin Receptor
25%
Hypoxia Inducible Factor 1
25%
Platelet Derived Growth Factor
25%
Raf Protein
25%
Thinking
25%
Patient
25%
Therapeutic Procedure
25%
INIS
therapy
75%
growth factors
75%
hepatomas
50%
clinical trials
25%
patients
25%
tumors
25%
reviews
25%
receptors
25%
kinases
25%
ischemia
25%
angiogenesis
25%
hypoxia
25%
Pharmacology, Toxicology and Pharmaceutical Science
Sorafenib
100%
Liver Cell Carcinoma
50%
Clinical Trial
50%
Combination Therapy
25%
Ischemia
25%
Vasculotropin
25%
Platelet Derived Growth Factor
25%
Vasculotropin Receptor
25%
Hypoxia Inducible Factor 1
25%
Raf Protein
25%